A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.” ...

An expert discusses that while CAR T-cell therapy has transformed the treatment landscape for primary refractory diffuse ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the urgent need for a shift in therapeutic strategy following early relapse ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

Lantern Pharma (LTRN) announced that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma ...

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

Glofitamab is a bispecific CD20-directed CD3 T-cell engager approved under the brand name Columvi ® for the treatment of adults with R/R DLBCL, not otherwise specified or large B-cell lymphoma arising ...

Combining duvelisib and romidepsin may provide a path to stem cell transplant for patients with relapsed or refractory peripheral and cutaneous T-cell lymphomas.  Researchers from Somerville, ...